FEI announces adverse drug findings in two competition horses

The FEI has announced two new adverse findings in horses involving prohibited substances.

Samples taken at the CSIO2* in Tehran, Iran, late in September from the showjumping horse Sir de Diamant, ridden by Mohammad Davoud Shekofti, of Iran, were positive for the banned substance stanozolol and its metabolite, 16 beta hydroxy-stanozol. It is an anabolic steroid that promotes muscle mass.

The horse’s sample also tested positive for the controlled medication dexamethasone, a corticosteroid used to treat inflammatory and auto-immune conditions, and the non-steroidal anti-inflammatory drug flunixin.

Samples taken at the Young Horse Endurance Championships in Valeggio sul Minico, Italy, on September 26 from the horse Barbaforte Bosana, ridden by Camilla Malta, of Italy, have tested positive for the banned substance ergonovine, a vasoconstrictor.

Both athletes have been provisionally suspended from November 16 – the date of notification. The horses have been provisionally suspended for two months.

Read more at Horsetalk.co.nz